10x Genomics Inc.

TXG | NASDAQ

Price Alert Chart Builder DCF Calculator

$70.11

-$11.44 (-14.03%)

At close: Oct 30, 2026, 4:00 PM ET

$71.51

+$1.40 (+2.00%)

Pre-market: Nov 2, 2026, 4:01 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-14.03%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

41.3

+0.5 pts

Fundamentals Average

Market Sentiment Neutral

Moat Narrow

Sector Rank #502/1028 (Top 49%)

Full Analysis

Key Statistics

Market Data

Market Cap $9.13B

1D Range

67.47 75.79

52W Range

13.00 97.74

Valuation (TTM)

PE -118.83

PB 11.07

EV/EBITDA 309.29

Valuation (NTM)

Forward PE N/A

Forward PEG -1.59

Price Target $83.30

Cash Flow

FCF Yield 1.3%

SBC Adj. FCF Yield 0.3%

SBC Impact -81.3%

Margins

Gross Margin 70.0%

Operating Margin -14.3%

FCF Margin 19.7%

Growth (CAGR)

Revenue 3Y | 5Y 2.8% | 8.7%

Dil EPS 3Y | 5Y 64.8% | 17.6%

FCF 3Y | 5Y 160.4% | 275.7%

Returns

ROA -7.3%

ROE -9.3%

ROIC -9.6%

Financial Health

Net Cash

$540.02M

Current Ratio 5.69

Interest Coverage -29,461.33

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializ...

Sector Healthcare

Industry Biotechnology

Employees 1,178

IPO Date Sep 12, 2019

Website www.10xgenomics.com

Fiscal Year January - December

Full Company Profile

Latest News

17 days ago · gurufocus.com

A Look at 10x Genomics Inc (TXG) After 3.5% Decline -- GF Value $18.31 vs Price $69.86

On October 16, 2026, 10x Genomics Inc (TXG) shares fell 3.5%, bringing the current price to $69.86. The stock has experienced significant price fluctuations, wi

20 days ago · prnewswire.com

10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026

PLEASANTON, Calif., Oct. 13, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial results for the third quarter ended September 30, 2026 after market close on Thursday, November 5, 2026.

25 days ago · zacks.com

10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research

TXG teams up with Fred Hutchinson Cancer Center to advance precision oncology through single-cell and spatial technologies targeting two cancer types.

26 days ago · prnewswire.com

10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers

Multi-project collaboration with Fred Hutch Cancer Center spans biomarker discovery in bladder cancer and a single cell approach to residual disease detection in acute myeloid leukemia PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a multi-project research collaboration with Fred Hutchinson Cancer Center (Fred Hutch), one of the nation's leading cancer research institutions, to advance the use of single cell and spatial technologies in both solid tumor and hematologic malignancies.

1 month ago · zacks.com

10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises

TXG begins Atera shipments as orders top 40 systems, highlighting strong early demand and broad research interest in its spatial biology platform.

1 month ago · prnewswire.com

10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions

Sentira Spatial Analysis leverages NVIDIA accelerated computing to cut spatial data processing times from hours to minutes, putting rapid, iterative analysis at the fingertips of every researcher PLEASANTON, Calif., Sept. 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced Sentira, a new cloud analysis platform that extends the 10x experience from data generation to experimental conclusions, beginning with Sentira Spatial Analysis.

1 month ago · gurufocus.com

10x Genomics Inc (TXG) Shares Surge 3.3% -- What GF Score of 56 Tells Investors

On September 21, 2026, 10x Genomics Inc (TXG) shares rose 3.3% to a current price of $79.10. The stock has seen a remarkable performance over the past year, wit

2 months ago · prnewswire.com

Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research

10x Genomics, a leader in single-cell and spatial biology, to combine its spatial biology technologies with Lunit's AI-powered H&E pathology analysis to advance oncology biomarker discovery SEOUL, South Korea, Sept. 10, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 10x Genomics, Inc. (Nasdaq: TXG) will incorporate Lunit's AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow.

2 months ago · gurufocus.com

10x Genomics Inc (TXG) Stock Up 4.7% but GF Value Says Overvalued -- GF Score: 56/100

On September 08, 2026, 10x Genomics Inc (TXG) shares rose 4.7% today, bringing the current price to $65.61. The stock has seen significant volatility over the p